QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
QQQ   361.26 (+0.83%)
AAPL   173.75 (+1.48%)
MSFT   321.80 (+1.92%)
META   306.82 (+2.20%)
GOOGL   134.17 (+2.53%)
AMZN   129.46 (+1.84%)
TSLA   251.60 (+0.55%)
NVDA   447.82 (+2.95%)
NIO   8.79 (-2.77%)
BABA   86.53 (-0.24%)
AMD   103.27 (+0.44%)
T   14.67 (-2.33%)
F   12.31 (-0.97%)
MU   67.96 (-0.10%)
CGC   0.74 (-6.35%)
GE   108.79 (-1.59%)
DIS   81.67 (+0.76%)
AMC   8.16 (+2.00%)
PFE   33.94 (+2.32%)
PYPL   58.56 (+0.17%)
NFLX   380.33 (+0.72%)
NASDAQ:OMER

Omeros (OMER) Stock Forecast, Price & News

$2.77
-0.15 (-5.14%)
(As of 10/2/2023 ET)
Compare
Today's Range
$2.76
▼
$2.92
50-Day Range
$2.81
▼
$5.14
52-Week Range
$1.74
▼
$7.80
Volume
475,352 shs
Average Volume
677,101 shs
Market Capitalization
$174.12 million
P/E Ratio
4.33
Dividend Yield
N/A
Price Target
$8.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Omeros MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
188.8% Upside
$8.00 Price Target
Short Interest
Bearish
20.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.30
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.10) to ($1.85) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

397th out of 969 stocks

Pharmaceutical Preparations Industry

167th out of 452 stocks

See Top Rated MarketRank™ Stocks Here

OMER stock logo

About Omeros (NASDAQ:OMER) Stock

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

OMER Price History

OMER Stock News Headlines

August 24, 2023 | msn.com
Omeros: Where Medical Hopes Tangle With Fiscal Ropes
August 23, 2023 | msn.com
Omeros: Betting Big On Narsoplimab, We Are Still A Buyer
October 2, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
August 15, 2023 | finance.yahoo.com
Institutions own 40% of Omeros Corporation (NASDAQ:OMER) shares but individual investors control 56% of the company
August 9, 2023 | msn.com
Omeros GAAP EPS of -$0.70 misses by $0.13
August 9, 2023 | finance.yahoo.com
Omeros Corporation Reports Second Quarter 2023 Financial Results
August 8, 2023 | seekingalpha.com
Omeros Q2 2023 Earnings Preview
August 4, 2023 | finance.yahoo.com
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
October 2, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
July 25, 2023 | money.usnews.com
Omeros Corporation
June 26, 2023 | finance.yahoo.com
Monoclonal Antibodies Industry Analysis 2023: 180+ Companies, 230+ Drugs, Therapeutics Assessment, Inactive Pipeline Products, Unmet Needs
June 23, 2023 | finance.yahoo.com
Global Monoclonal Antibodies Market Landscape Assessment 2023: Developments, Trends, Competitors and Products
June 12, 2023 | finance.yahoo.com
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
June 12, 2023 | finance.yahoo.com
Why Shares of Omeros Dropped on Monday
June 1, 2023 | seekingalpha.com
OMER, TWST and RXTR are among after hour movers
June 1, 2023 | finance.yahoo.com
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
May 17, 2023 | msn.com
Unusual Call Option Trade in Omeros (OMER) Worth $30.00K
May 16, 2023 | msn.com
Omeros: Q1 Earning Overview, Best Contrarian Biotech Play Of 2023
May 11, 2023 | msn.com
Omeros Q1 2023 Earnings Preview
May 11, 2023 | msn.com
Earnings Preview: Omeros
May 11, 2023 | apnews.com
Omeros: Q1 Earnings Snapshot
May 11, 2023 | msn.com
Omeros: Q1 Earnings Insights
May 10, 2023 | benzinga.com
Omeros Stock (NASDAQ:OMER), Dividends
May 9, 2023 | finance.yahoo.com
Omeros Corporation Reports First Quarter 2023 Financial Results
May 4, 2023 | finance.yahoo.com
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
April 25, 2023 | finance.yahoo.com
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
April 12, 2023 | bizjournals.com
Omeros lands $6.7M grant to test treatment for cocaine addiction
See More Headlines
Receive OMER Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omeros and its competitors with MarketBeat's FREE daily newsletter.

OMER Company Calendar

Last Earnings
8/09/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:OMER
CUSIP
68214310
CIK
1285819
Web
www.omeros.com
Phone
(206) 676-5000
Fax
206-676-5005
Employees
196
Year Founded
1994

Price Target and Rating

Average Stock Price Forecast
$8.00
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+174.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$0.64
Trailing P/E Ratio
4.56
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$47.42 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-643.87%
Return on Assets
-34.61%

Debt

Debt-to-Equity Ratio
10.80
Current Ratio
2.71
Quick Ratio
2.71

Sales & Book Value

Annual Sales
$73.81 million
Price / Sales
2.49
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.37 per share
Price / Book
2.13

Miscellaneous

Outstanding Shares
62,860,000
Free Float
56,005,000
Market Cap
$183.55 million
Optionable
Optionable
Beta
0.99

Social Links

The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Gregory A. Demopulos M.D. (Age 64)
    Co-Founder, Chairman, CEO & Pres
    Comp: $1.79M
  • Mr. Michael A. Jacobsen (Age 65)
    Chief Accounting Officer, VP of Fin. & Treasurer
    Comp: $518.6k
  • Mr. Peter B. Cancelmo J.D. (Age 44)
    VP, Gen. Counsel & Corp. Sec.
    Comp: $503.24k
  • Dr. Pamela Pierce Palmer M.D. (Age 60)
    Ph.D., Co-Founder
  • Dr. George A. Gaitanaris M.D. (Age 66)
    Ph.D., Chief Scientific Officer & VP of Science
  • Mr. Peter W. Williams (Age 55)
    VP of HR
  • Dr. J. Steven Whitaker J.D. (Age 67)
    M.D., VP of Clinical Devel. & Chief Medical Officer
  • Dr. Catherine A. Melfi Ph.D. (Age 64)
    Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems
  • Ms. Nadia Dac (Age 53)
    VP & Chief Commercial Officer
  • Ms. Debra K. Bowes M.T (Age 63)
    VP & Chief Bus. Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













OMER Stock - Frequently Asked Questions

Should I buy or sell Omeros stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OMER shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OMER, but not buy additional shares or sell existing shares.
View OMER analyst ratings or view top-rated stocks.

What is Omeros' stock price forecast for 2023?

3 brokers have issued twelve-month price objectives for Omeros' shares. Their OMER share price forecasts range from $3.00 to $13.00. On average, they anticipate the company's share price to reach $8.00 in the next year. This suggests a possible upside of 174.0% from the stock's current price.
View analysts price targets for OMER or view top-rated stocks among Wall Street analysts.

How have OMER shares performed in 2023?

Omeros' stock was trading at $2.26 at the start of the year. Since then, OMER shares have increased by 29.2% and is now trading at $2.92.
View the best growth stocks for 2023 here.

When is Omeros' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our OMER earnings forecast.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.10.

What is Gregory A. Demopulos' approval rating as Omeros' CEO?

17 employees have rated Omeros Chief Executive Officer Gregory A. Demopulos on Glassdoor.com. Gregory A. Demopulos has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Omeros own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omeros investors own include ACADIA Pharmaceuticals (ACAD), Exelixis (EXEL), Array Technologies (ARRY), Inovio Pharmaceuticals (INO), Ocular Therapeutix (OCUL), Alibaba Group (BABA), Sangamo Therapeutics (SGMO), Verastem (VSTM), Bausch Health Companies (BHC) and Celldex Therapeutics (CLDX).

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How do I buy shares of Omeros?

Shares of OMER stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $2.92.

How much money does Omeros make?

Omeros (NASDAQ:OMER) has a market capitalization of $183.55 million and generates $73.81 million in revenue each year. The biopharmaceutical company earns $47.42 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does Omeros have?

The company employs 196 workers across the globe.

Does Omeros have any subsidiaries?
The following companies are subsidiares of Omeros: Nura.
Read More
How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The official website for the company is www.omeros.com. The biopharmaceutical company can be reached via phone at (206) 676-5000, via email at ir@omeros.com, or via fax at 206-676-5005.

This page (NASDAQ:OMER) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -